Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Biotechnology

Healthcare
$1.86 -1.41%

-$0.02 today

Market cap
$141.41M
Beta
2.08
P/E (TTM)
-25.1
EPS (TTM)
-$0.06
52W Low $1.43High $67.00

Volume 0.07M

Average 0.10M

MENS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS

Selling, General & Admin · Q4 FY2025 · quarter ended Dec 2025

Selling, general & admin grows 397241.2% year over year

Q4 FY2025 selling, general & admin of $1.35M rose 397241.2% year over year. Over 3 fiscal years it compounded at +4.9% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$1.35M— QoQ
Last fiscal yearDec 2025
$1.78M+57.3% YoY
LTMDec 2024
$1.13K— YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+397241.2%——
1 year+57.3%——
3-year CAGR+4.9%——
5-year CAGR——
10-year CAGR——

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
1.78M USD
Year-over-year change
+57.3%
4-year CAGR
+20.4%

Selling, General & Admin vs competitors

How MENS compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of +4.9% compares with a peer median of +29.8%.
MENS Competitors
Selling, General & Admin for MENS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥522.67M CNY+36.4%+16.8%93.6%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$376.47M USD+23.4%+19.5%57.8%
LEGNLegend Biotech CorporationLTM Sep 2026$357.49M USD+10.5%+25.2%26.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$350.27M USD+5.7%+7.9%52.3%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$94.24M USD+24.7%+34.4%—
DYNDyne Therapeutics, Inc.LTM Jun 2026$91.25M USD+50.5%+35.3%—
CGONCG Oncology, Inc. Common stockLTM Sep 2026$90.71M USD+34.9%+125.7%1471.2%
APGEApogee Therapeutics, Inc.LTM Jun 2026$83.07M USD+33.3%+188.9%—
CELCCelcuity Inc.LTM Jun 2026$71.99M USD+448.5%+83.8%—
CNTACentessa Pharmaceuticals plcLTM Mar 2026$58.02M USD+16.7%-2.9%—
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 2024$1.13K USD—+4.9%—
Peer median (excluding MENS) —+29.0%+29.8%57.8%

Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue121K122K127K120K100K
Gross Profit(121K)(122K)(127K)(120K)(100K)
Gross Margin—————
Research & Development1.56M1.29M1.07M927K731K
Selling, General & Admin845K1.54M1.73M1.13M1.78M
Operating Expenses2.4M2.83M2.8M2.06M2.51M
Depreciation & Amortization122K123K127K120K100K
EBITDA(3.24M)(5.74M)(3.52M)(1.86M)(2.51M)
EBITDA Margin—————
Operating Income(2.4M)(2.83M)(2.8M)(2.06M)(2.61M)
Operating Margin—————
Interest Income6K5K56K7K610K
Interest Expense835K765K757K1.04M2.54M
Other Income / Expenses(1.79M)(3.8M)(1.6M)(963K)(2.06M)
Income Before Tax(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Net Margin—————
EPS (Basic)(0.06)(0.09)(0.06)(0.04)(0.06)
EPS (Diluted)(0.06)(0.09)(0.06)(0.04)(0.06)
Weighted Avg Shares76.03M76.03M76.03M76.03M73.01M
Weighted Avg Shares (Diluted)76.03M76.03M76.03M76.03M73.01M

Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Intrinsic Alpha fair value

Locked

Current Price

$1.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.